Documents / Official release
This Defense Intelligence Reference Document, dated 7 January 2010, was prepared by the Defense Intelligence Agency's Defense Warning Office. It is one of a series of advanced technology reports produced in FY 2009 under the Advanced Aerospace Weapon System Applications program. The report reviews biomaterials used in medicine, including silicones, Teflon, biodegradable polymers, hydrogels, titanium, ceramics and tissue constructs, and applications such as stents, joints, contact lenses, drug delivery and dialysis. It concludes that most innovation lies in new ways to apply existing materials.
From the source:Release of 2026-09-18 Incident: 1/7/10, Las Vegas, Nevada. Released with redactions. This document is a Defense Intelligence Reference Document (DIRD), a technical reference format used by the Defense Intelligence Agency (DIA) to capture baseline knowledge on a specific topic for later analytic use. DIRDs are best understood as reference and synthesis products rather than as original research. It is one of 38 DIRDs produced under the Advanced Aerospace Weapon System Applications Program (AAWSAP) between 2009 and 2011. Because AAWSAP’s scope permitted a broad range of supporting topics, not every DIRD in the series directly concerns aerospace systems or future threat assessment. The following summary reflects the DIRD’s scope and framing at the time of writing and should not be read as implying current validation of the concepts discussed. This DIRD is a broad survey of biomaterials, including metals, polymers, ceramics, glasses, and composites designed to interact with living tissue, and argues that their value depends mainly on biocompatibility, reliability, and careful matching of material properties to specific medical uses. The report reviews major application areas including biosensors, implants, cardiovascular devices, contact lenses, drug delivery systems, tissue constructs, titanium devices, and dialysis membranes, emphasizing that no single biomaterial works best in every setting. Its overall conclusion is that biomaterials are already foundational to a large medical-device industry and save or improve millions of lives, but that progress tends to be slow because safety testing is stringent; as a result, most advances come from improved ways of applying established materials such as silicone, Teflon, biodegradable polymers, ceramics, and titanium in new devices and clinical settings rather than from radically new substances.
UNCLASSIFIED// FOR OFFICl,CL l:ISI!!! 8HL'f the active agent in a biodegradable polymer, as shown in Figure 28. The polymer host to the drug dissolves, releasing the drug in a controlled manner over time. polym r ••• •• •• •• • ••••• • • drug time - 0 time - t Figure 26. Schematic Representation of Biodegradable (Bioerodible} Drug Delivery Device The use of biodegradable materials allows the drug to be introduced without much concern for the build-up of the polymer carrier. The carrier is eventually absorbed by the body and, thus, need not be removed surgically. Drug diffusion through the polymer matrix can also determine the drug dosage rate without actual loss of the polymer. This rate is determined by the choice of polymer, the size of its pores, and the rate at which the drug diffuses from the pores. The three key advantages polymeric drug delivery products can offer are: • Localized Delivery of Drugs: The polymer-drug combination can be implanted directly at the site where drug action is needed and, hence, whole-body exposure of the drug can be reduced. This becomes especially important for toxic drugs, such as the chemotherapeutic drugs. • Sustained Delivery of Drugs: Once injected, the encapsulated drug is released over extended periods, thereby eliminating the need for multiple injections. This feature can improve patient compliance, especially with drugs for chronic indications that require frequent injections (such as for deficiency of certain proteins). • Stabilization of the Drug: The polymer can protect the drug from the physiological environment and hence improve its stability in vivo. This particular feature makes this technology attractive for the delivery of labile drugs, such as proteins. UNCLASSIFIED/ fFOA QFFICiI> .. U&'li ODIL¥ 21
Not linked to a story yet.
Official release, from the pursue collection. The PDF is mirrored here; the original link is above. 32 pages are in the text index: search them above, or from the library's search.